← Back to Search

Control for Inflammatory Bowel Disease

N/A
Waitlist Available
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years.
Awards & highlights
No Placebo-Only Group

Summary

The main objective of this study is to determine the role of epithelial cell homeostasis in the pathogenesis of intestinal diseases. Background: Alterations in intestinal barrier function may play a significant role in the pathogenesis of chronic intestinal diseases such as inflammatory bowel disease (IBD). The intestinal epithelium functions as a barrier to the luminal contents, thereby preventing undesirable solutes, micro-organisms and other luminal antigens from entering the body. Confocal endomicroscopy has recently been shown that increased epithelial cell shedding may contribute to increased intestinal permeability, at least locally. In our study, we want to determine the contribution of epithelial cell shedding to intestinal permeability in vivo in patients with inflammatory bowel disease compared to controls. Scope: In inflammatory bowel disease patients and controls (patients undergoing endoscopy for other indications). Methods: We will perform confocal endoscopy during the patient's endoscopic procedure. Procedure: The patient will receive intravenous fluorescein, followed by confocal imaging of the gastrointestinal tissue. The images are captured on the computer. The proposed study will provide important insights into epithelial cell shedding as a contributor to altered intestinal permeability.

Eligible Conditions
  • Inflammatory Bowel Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The intestinal morphology as visualized using confocal laser endomicroscopy
Secondary study objectives
Clinical outcome and pathologic/molecular correlation with intestinal morphology

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Diseased groupExperimental Treatment1 Intervention
Patients with Crohn's disease or ulcerative colitis undergoing endoscopy.
Group II: ControlExperimental Treatment1 Intervention
In patients undergoing endoscopy for indications other than Crohn's disease or ulcerative colitis
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Confocal endomicroscopy
2009
N/A
~350

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
940 Previous Clinical Trials
433,811 Total Patients Enrolled
~14 spots leftby Nov 2025